Figure 2.
Estimated range of % of patients who develop infections over time with CD19-directed and BCMA-directed CAR T-cells (recognizing variations in reporting and criteria used) derived from refs.6,7,10-13,30,32,40 *Data in BCMA-CAR-T recipients are limited.

Estimated range of % of patients who develop infections over time with CD19-directed and BCMA-directed CAR T-cells (recognizing variations in reporting and criteria used) derived from refs.6,7,10-13,30,32,40 *Data in BCMA-CAR-T recipients are limited.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal